{"entity":{"id":"aadi-bioscience","kind":"company","name":"Aadi Bioscience","aka":["Whitehawk Therapeutics","Aadi Bioscience, Inc.","NASDAQ:AADI"],"tldr":"Aadi Bioscience won approval for Fyarro, the albumin-bound sirolimus that treats the rare sarcoma PEComa, then sold it and renamed itself Whitehawk Therapeutics to develop antibody-drug conjugates.","summary":"Aadi Bioscience developed nab-sirolimus (Fyarro, ABI-009), an mTOR inhibitor bound to albumin nanoparticles for better tumour delivery. The FDA approved it in November 2021 for malignant perivascular epithelioid cell tumour, the first drug for that sarcoma; the PRECISION 1 trial tested it in tumours with TSC1 or TSC2 alterations. In 2025 Aadi sold Fyarro to Kaken Pharmaceutical, in-licensed three antibody-drug conjugates from WuXi Biologics and Hangzhou DAC, and became Whitehawk Therapeutics.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.aadibio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sirolimus-albumin-bound"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Los Angeles, California","country":"US","companyType":"biotech","website":"https://www.aadibio.com/","ticker":"NASDAQ:AADI","stage":"public","investors":[],"funding":[]},"route":"/companies/aadi-bioscience/","neighbours":{"drug":[{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/"}]}}